Throughout history, women have played a vital role in the field of cancer. This #InternationalWomensDay and throughout #WomensHistoryMonth, join us in celebrating the female physicians, researchers, and educators who have been trailblazers in cancer research, advocacy, and medicine.
GRAIL
Biotechnology Research
Menlo Park, CA 91,457 followers
Detect cancer early, when it can be cured.
About us
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit grail.com. Community Guidelines: https://bit.ly/3xigb24
- Website
-
http://www.grail.com
External link for GRAIL
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Menlo Park, CA
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Cancer Detection, Cancer Biology, Clinical Trials, Computer Science, Machine Learning, and Data Science
Locations
-
Primary
Get directions
1525 O'Brien Drive
Menlo Park, CA 94025, US
Employees at GRAIL
Updates
-
Roger’s story is a reminder of the impact of proactive cancer screening. He is now cancer-free after undergoing treatment for pancreatic cancer, one of the deadliest types of cancer. Listen to Roger's full story on The Cancer SIGNAL podcast: https://bit.ly/40n8bvC
-
Kate Walsh’s personal connection to cancer, through both of her parents’ diagnoses, highlights how their generation did not have the options we have today to screen for cancer. That’s why Kate is part of Generation Possible - the first generation with access to multi-cancer early detection (MCED) testing in addition to recommended single-cancer screenings. Visit GenPossible.com to hear Kate’s story and see Important Safety Information.
-
-
Today GRAIL reported fourth quarter and full year 2024 financial results. Read more: https://bit.ly/3CXTOFm
-
-
Jack’s path to a cancer diagnosis was anything but straightforward. See how two Cancer Signal Detected results from multi-cancer early detection (MCED) screening tests taken six months apart helped his care team determine the necessary diagnostics that confirmed an early stage cancer diagnosis. Rx only. See Important Safety Information: https://bit.ly/3QHmPWo #CancerScreening #MCED #PatientStory
-
“What if you caught cancer early enough to make a difference?” Gracie learned about multi-cancer early detection (MCED) testing through a workplace bulletin, offering it as a benefit. Though she had no symptoms of cancer, she took the test and was surprised to receive a Cancer Signal Detected result. Watch her story below. #CancerScreening #MCED #PatientStory Rx only. See Important Safety Information: https://bit.ly/3QHmPWo
-
#BRCA1 promoter methylation is a cancer susceptibility marker with prognostic value in breast and ovarian cancer. Using GRAIL’s tissue-free assay, we detected and quantified BRCA1 promoter hypermethylation in cell-free DNA from a large case-control study of cancer and non-cancer populations (https://lnkd.in/gwvngUji). Meet with our biopharma team ([email protected]) at the 9th Annual Liquid Biopsy for Precision Oncology Summit to learn more about how GRAIL’s methylation platform can address your biopharma needs. #tissuefree #methylation #ctDNA #liquidbiopsy #PrecisionOncology
-
-
We will issue financial results for the fourth quarter 2024 on Thursday, February 20, 2025. Register for the live teleconference: https://bit.ly/4aVOej8 See more details: https://bit.ly/42SiI3C
-
-
Today we announced that the Galleri Test is now available directly to physicians in the U.S. through a collaboration with Quest Diagnostics, delivering a more streamlined provider and patient experience. Patients can now go directly to Quest without needing to bring a Galleri test kit or a test requisition form to the blood draw appointment. Learn more and see Important Safety Information: https://bit.ly/3QiiRpH Rx only.
-
-
This #BlackHistoryMonth, we are honoring pioneers in cancer research, advocacy and medicine—Black physicians, researchers, educators and others who have revolutionized how we prevent, screen, and treat cancer, particularly in Black and underserved communities. From renowned historical figures to individuals who are still actively working to improve the lives of those touched by cancer, these are just some of the Black leaders who have had a significant impact.